Daprodustat compared with epoetin alpha for anemia in chronic kidney disease without dialysis
Compares daprodustat with epoetin alpha for anemia in adults with kidney disease, not on dialysis.
Plain-language title generated from the registry record
Registry title: Effect of Daprodustat and Epoetin Alpha on Anemia in Patients Not Undergoing Dialysis
Key facts
- Where
- Lahore, PakistanSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07755683, who can take part
Where in Pakistan
- Services Hospital Lahore PakistanLahore, PakistanNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Services Hospital, Lahore
- Trial code
- NCT07755683
- Record updated
- 10 August 2026
- Original description
Anemia in CKD patients is mainly attributed to impaired kidney being unable to adequately respond to hypoxia and/or anaemia by inducing erythropoietin (EPO) production iron disorders, blood loss, shortened erythrocyte survival time and inflammation. High mortality among patients with advanced renal failure is directly related to the severity of anemia and hypoalbuminemia, particularly within the first six months.4, 5 Currently, the main treatment modalities for anemia in CKD include injections of erythropoiesis stimulating agents (ESAs), iron supplementation, and blood transfusion. EPO resistance and iron refractory anemia require red blood cell transfusions.Read full original descriptionShow less
Effect of Daprodustat and Epoetin Alpha on Anemia in Patients Not Undergoing Dialysis
Anemia in CKD patients is mainly attributed to impaired kidney being unable to adequately respond to hypoxia and/or anaemia by inducing erythropoietin (EPO) production iron disorders, blood loss, shortened erythrocyte survival time and inflammation. High mortality among patients with advanced renal failure is directly related to the severity of anemia and hypoalbuminemia, particularly within the first six months.4, 5 Currently, the main treatment modalities for anemia in CKD include injections of erythropoiesis stimulating agents (ESAs), iron supplementation, and blood transfusion. EPO resistance and iron refractory anemia require red blood cell transfusions.
The rationale of this study is to compare the effectiveness of daprodustat versus epoetin alpha on hemoglobin level in patients with chronic kidney disease not on hemodialysis. Literature showed that epoetin alpha has better effectiveness in improving hemoglobin level and curing anemia in CKD patients. But conflicting results have been osbevred showing no difference in both drugs. In routine, both drugs are recommended for anemia in non-dialysis CKD patients. This trial is planned to check the effect of Daprodustat in patients not undergoing dialysis is primarily to provide an effective, orally administered alternative to current injectable anemia treatments, which are associated with several limitations and safety concerns. The treatment strategies and effectiveness optimization for patients with chronic kidney disease complicated by anemia remain a key issue that urgently needs to be addressed.
Inclusion: Age 18-65 years, either gender; Confirmed CKD stage 3, 4, or 5; Not currently receiving dialysis at time of screening; Hemoglobin at presentation: 8.0-10 g/dL, serum ferritin > 100 ng/mL at screening and transferrin saturation (TSAT) > 20% at screening.
Exclusion: Use of any experimental/investigational drug within 30 days of screening or know hypersensitivity against trial drugs; Clinically significant gastrointestinal bleeding, major surgery or RBCs transfusion in last 4 weeks; Uncontrolled hypertension (>180/100 mmHg); Active or high risk malignancy or treatment for malignancy with in the past 2 years; Recent major cardiovascular event including acute coronary syndrome or stroke, or in the past 3 months, chronic liver disease (ALT OR AST > 40 IU, hepatitis B or C); Acute sepsis as evident by increase C-reactive protein (CRP), Total leukocyte count (TLC); Pregnant, breast-feeding, not agreed to use contraception; Uncorrected iron deficiency despite iron supplementations.